Christopher M. Riley, president of Riley and Rabel Consulting Services Inc., will give a two-part seminar titled "HPLC is the worst technique for the quantitative analysis of drugs and drug impurities — Except for all the others: Determination of vancomycin impurities in Dry Powder Inhalation Product — A case in point!" from 3-5 p.m. on Friday, Nov. 19. Everyone is welcome to attend the seminar via Zoom or in person in CHEM 144. The talk is free and open to the public.

Riley is the president and co-founder of Riley and Rabel Consulting Services Inc. Riley received his bachelor's degree in pharmacy (1977) and Ph.D. degree in pharmaceutical chemistry (1980) from the University of Bath, England. He was a post-doctoral fellow at the University of Kansas in the Department of Pharmaceutical Chemistry (1981-1982) before joining the faculty of the Department of Pharmaceutics at the University of Florida. He returned to the University of Kansas as a faculty member in 1986, where he remained until 1994.

Riley's industrial experience began in 1994 as head of analytical R&D at Dupont Pharmaceuticals (previously Dupont Merck). In late 2001 he joined ALZA, a subsidiary of Johnson & Johnson, where he had positions of increasing responsibility up to vice president and West Coast site head ChemPharm Development. He left ALZA in May 2007 to form Riley and Rabel Consulting Services. He has co-authored more than 100 book chapters and papers in peer-reviewed journals, as well as two books entitled Pharmaceutical and Biomedical Applications of Liquid Chromatography and Validation of Methods and Systems in Pharmaceutical and Biomedical Analysis. He was elected Fellow of the American Association of Pharmaceutical Scientists (AAPS) and served as the chair of the Analysis and Pharmaceutical Quality Section of AAPS and a Member of the AAPS Executive Committee. Riley has served as a member and chair of the PhRMA Analytical Technical Committee, as well as a member and chair of the PhRMA Technical Leadership Committee. Riley represented PhRMA on the ICH Expert Working Group on Impurities in Drug Substances (Q3A) and Drug Products (Q3B) and was chair of the PhRMA Working Group on Genotoxic Impurities.

Starting at 3 p.m., part one will be an informal discussion of some of the requirements for analytical methods in a regulated industry, in this case the requirements for analytical methods used in the development and commercialization of new drugs. At 4 p.m., Riley will give a presentation on the development and validation of a method for the determination of the impurities in vancomycin and the problems caused by the loss of separation of three critical pairs of peaks after almost two years of use and analysis of thousands of samples.

To attend the seminar virtually, please visit the Zoom link.
Meeting ID: 870 1464 3915
Password: jq8WX=Dg